Special pathological reporting is important in patients going through neoadjuvant systemic therapy (NST). There exist at least five different reporting scores to the quality of remission right after NST; Many of these, however, are only validated for inflammatory breast most cancers (e.Depending upon the spot with the tumor, the mammillary and areo